NTCELL Parkinsons trial patient data at 18 months
Filed with ASX · · 3 pages · English
Algorae Pharmaceuticals Limited on 6ix
Story so far
Earlier from Algorae Pharmaceuticals
- Preliminary Final Report and 2018 Financial Statements
- NTCELL and Parkinsons trial update
- LCT Strategy Update
- LCT to sell JV Shares and receive DIABECELL licence
- Appendix 4C - Quarterly
Later from Algorae Pharmaceuticals
- NTCELL Parkinsons trial patient data 2 years after implant
- Preliminary Final Report and 2019 Financial Statements
- LCT to benefit from Semma Therapeutics acquisition by Vertex
- LCT extends cash runway with receipt from Vertex acquisition
- Response to ASX Aware Query
Follow Algorae Pharmaceuticals into a list and get an email when it puts out news.
Follow Algorae Pharmaceuticals